UFT Plus Carboplatin for Head and Neck Cancer
ByMasato Fujii, MD,Yoshihiro Ohno, MD,Yutaka Tokumaru, MD,Yorihisa Imanishi, MD,Minoru Kanke, MD,Toshiki Tomita, MD,Taku Yamashita, MD
Published: | Updated:
Cisplatin plus fluorouracil (5-FU) is widely accepted as neoadjuvant and adjuvant chemotherapy in the treatment of head and neck squamous cell carcinoma; UFT is also an active agent against this disease. In the first retrospective study, we examined the efficacy of UFT as adjuvant chemotherapy in patients with maxillary cancer.